PEOPLE ON THE MOVE
Pertinax: Nigel Brooksby
Pertinax Pharma has appointed Sanofi-alumni Nigel Brooksby as chairman.
The UK-based firm is developing antimicrobial material which it says aims to overcome the short duration of antimicrobial activity of conventional chlorhexidine (CHX) products.
In the role, Brooksby will focus on corporate, strategic and business development activities as the firm’s antimicrobial technology advances to commercialisation.
“I’m looking forward to working from [founder Michele Barbour] and her Pertinax team to make a real difference to healthcare,” Brooksby told us.
The firm is already in talks with manufacturers, and expects to have applications of Pertinax in development by next year, he said in a statement.
Brooksby has previously held senior positions at UK Life Sciences Strategy Board, the Association of the British Pharmaceutical Industry (ABPI), Pfizer, and Sanofi, where he was a member of the Sanofi Executive Committee in Europe and America and chairman and managing director of the Sanofi Group in the UK and Ireland.
He is a non-executive director at Porton Biopharma and Chronos Therapeutics, chairman of Clinical Insights and Neurocentrx Pharma, and a director of Stabilitech Pharma.
